BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25081660)

  • 1. Analysis of indoleamine 2-3 dioxygenase (IDO) and EGFR co-expression in breast cancer tissue by immunohistochemistry.
    Bi WW; Zhang WH; Yin GH; Luo H; Wang SQ; Wang H; Li C; Yan WQ; Nie DZ
    Asian Pac J Cancer Prev; 2014; 15(14):5535-8. PubMed ID: 25081660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer.
    Ye Q; Wang C; Xian J; Zhang M; Cao Y; Cao Y
    Hum Pathol; 2018 May; 75():81-90. PubMed ID: 29447919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer.
    Zhao Y; Wei L; Liu J; Li F
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):77-93. PubMed ID: 31844921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan.
    Asghar K; Loya A; Rana IA; Abu Bakar M; Farooq A; Tahseen M; Ishaq M; Rashid MU
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3521-3525. PubMed ID: 31759380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry.
    Soliman H; Rawal B; Fulp J; Lee JH; Lopez A; Bui MM; Khalil F; Antonia S; Yfantis HG; Lee DH; Dorsey TH; Ambs S
    Cancer Immunol Immunother; 2013 May; 62(5):829-37. PubMed ID: 23344392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
    Chung YR; Kim HJ; Jang MH; Park SY
    Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of indoleamine 2,3-dioxygenase expression in patients with breast cancer].
    Sakurai K; Amano S; Enomoto K; Kashio M; Saito Y; Sakamoto A; Matsuo S; Suzuki M; Kitajima A; Hirano T; Negishi N
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1546-9. PubMed ID: 16315864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis.
    Isla Larrain MT; Rabassa ME; Lacunza E; Barbera A; Cretón A; Segal-Eiras A; Croce MV
    Tumour Biol; 2014 Jul; 35(7):6511-9. PubMed ID: 24687552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of indoleamine 2, 3-dioxygenase and its correlation with prognosis in breast cancer patients].
    Liu JT; Wei LJ; Yu JP; Li H; Li RM; Zang FL; Sun JY; Ren XB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):513-6. PubMed ID: 22093628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.
    Ino K; Yoshida N; Kajiyama H; Shibata K; Yamamoto E; Kidokoro K; Takahashi N; Terauchi M; Nawa A; Nomura S; Nagasaka T; Takikawa O; Kikkawa F
    Br J Cancer; 2006 Dec; 95(11):1555-61. PubMed ID: 17117179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy.
    Inaba T; Ino K; Kajiyama H; Shibata K; Yamamoto E; Kondo S; Umezu T; Nawa A; Takikawa O; Kikkawa F
    Gynecol Oncol; 2010 Jun; 117(3):423-8. PubMed ID: 20350764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
    Dill EA; Dillon PM; Bullock TN; Mills AM
    Mod Pathol; 2018 Oct; 31(10):1513-1522. PubMed ID: 29802358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
    Brandacher G; Perathoner A; Ladurner R; Schneeberger S; Obrist P; Winkler C; Werner ER; Werner-Felmayer G; Weiss HG; Göbel G; Margreiter R; Königsrainer A; Fuchs D; Amberger A
    Clin Cancer Res; 2006 Feb; 12(4):1144-51. PubMed ID: 16489067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer.
    Nishi M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Ishikawa D; Wada Y; Shimada M
    Anticancer Res; 2018 Jun; 38(6):3387-3392. PubMed ID: 29848687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of indoleamine 2,3-dioxygenase expression in patients of thyroid cancer].
    Sakurai K; Fujisaki S; Nagashima S; Shibata M; Maeda T; Ueda Y; Hara Y; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1927-9. PubMed ID: 22202241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.
    Jacquemier J; Bertucci F; Finetti P; Esterni B; Charafe-Jauffret E; Thibult ML; Houvenaeghel G; Van den Eynde B; Birnbaum D; Olive D; Xerri L
    Int J Cancer; 2012 Jan; 130(1):96-104. PubMed ID: 21328335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
    Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
    Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indoleamine 2, 3-dioxygenase and B7-H1 expressions as prognostic and follow-up markers in human pancreatic carcinoma.
    Wang L; Ma Q; Li D; Mu S; Li Y; Wang Y; Shi P; Yu H; Gao C; Guo K; Zhang Z
    Pathol Res Pract; 2018 Sep; 214(9):1309-1314. PubMed ID: 30029936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer.
    Zhang T; Tan XL; Xu Y; Wang ZZ; Xiao CH; Liu R
    Chin Med J (Engl); 2017 Mar; 130(6):710-716. PubMed ID: 28303855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.